American Society of HematologyHematology2019intermediate

Treatment of Immune Thrombocytopenia

Published by American Society of Hematology (ASH)

Summary

AI-generated

Immune Thrombocytopenia (ITP) is a rare autoimmune disorder where the immune system destroys platelets, causing significant bleeding episodes. The guidelines offer updated treatment evidence to optimize care and avoid unnecessary interventions, particularly in children.

immune thrombocytopeniaITPASHhematologyguidelinesrecommendationscorticosteroidssplenectomy

Key Takeaways

1
Avoid unnecessary treatment in children, as bleeding is minimal and disease often resolves without intervention.
2
Keep corticosteroid courses as short as possible to prevent harm.
3
Delay splenectomy for at least a year due to lifelong side effects.
4
Individualize choices between TPO-RAs and rituximab based on administration route, disease duration, treatment length, and co-morbidities.

Key Recommendations

WHAT THE GUIDELINES SAY

rec_1
Avoid unnecessary treatment in children, specifically interventions and treatments that have little evidence of success and may have side effects that outweigh potential benefits.
Treatment
rec_2
Keep the course of corticosteroid treatment as short as possible, as long-term corticosteroid use can cause harm without additional benefit.
Treatment
rec_3
Delay splenectomy for at least a year due to the life-long side effects that can result from the procedure.
Treatment
rec_4
When considering TPO-RAs and rituximab, consider differences in the route of administration, duration of disease, short versus long-term treatment, and patient co-morbidities to make the best choice for the individual patient.
Treatment

Scope & Objectives

Clinical Topic

Immune Thrombocytopenia

Objectives

Produce and maintain evidence-based guidelines that will support health care providers and patients in making the best care decisions.

Target Patient Population

Adults and children with Immune Thrombocytopenia (ITP)

Target Providers

HematologistsER physiciansPediatriciansPrimary care doctors

Patient Criteria & Setting

Therapeutic Area

Hematology

Guideline Scope

Treatment

Special Populations

ChildrenAdults

Safety & Contraindications

Monitoring Guidance

Provides guidance on how corticosteroid usage should be monitored.

Authors & Contributors

University of Oklahoma Health Sciences Center

Guideline Features

Based on systematic reviewMultidisciplinaryPatient involvement

Learning Context

Difficulty

intermediate

Learning Paths

HematologyPediatricsImmune ThrombocytopeniaAutoimmune DisordersShared Decision-Making